R124 reovirus

R124 reovirus is an experimental oncolytic mammalian orthoreovirus (MRV) derived from the Type 3 Dearing (T3D) strain. It is specifically engineered with a point mutation in the S1 gene segment, resulting in a proline-to-serine substitution at residue 124 (P124S) of the sigma 1 (σ1) attachment protein. This modification enables the virus to infect cells via a Junctional Adhesion Molecule-A (JAM-A)-independent pathway, likely by utilizing alternative receptors such as sialic acid. This expanded tropism allows R124 to target cancer cells that have downregulated JAM-A, a common mechanism of resistance to wild-type reovirus infection. Developed at Leiden University Medical Center (LUMC), R124 serves as a prototype for JAM-A independent (jin) mutants and has demonstrated preclinical efficacy in various tumor models, including prostate cancer and glioblastoma, by inducing direct oncolysis and stimulating anti-tumor immune responses.

Other names

124-mutant reovirusP124S reovirus mutantP-124S reovirus mutantP 124S reovirus mutant